EUVIMEDEUVIMED entdecken
Crossref

First-in-Humans PET Imaging of KRAS G12C Mutation Status in Non–Small Cell Lung and Colorectal Cancer Patients Using [ 18 F]PFPMD

Xiang Li, Jiajun Ye, Jingyi Wang, Zhiyong Quan, Guiyu Li, Wenhui Ma, Mingru Zhang, Weidong Yang, Junling Wang, Taoqi Ma, Fei Kang, Jing Wang

Journal of Nuclear Medicine · 2023-12 · 64 (12) · 1880-1888

DOI: 10.2967/jnumed.123.265715 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 12.10.2023. Verfasst von Xiang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Xijing Hospital, Fourth Milit…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kirsten rat sarcoma (KRAS) mutations are an important marker for tumor-targeted therapy. In this study, we sought to develop a KRASG12C oncoprotein-targeted PET tracer and to evaluate its translational potential for noninvasive imaging of the KRASG12C mutation in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) patients. Methods: [18F]PFPMD was synthesized on the basis of AMG510 (sotorasib) by attaching a polyethylene glycol chain to the quinazolinone structure. The binding selectivity and imaging potential of [18F]PFPMD were verified by cellular uptake, internalization, and blocking (H358: KRASG12C mutation; A549: non-KRASG12C mutation) studies, as well as by a small-animal PET/CT imaging study on tumor-bearing mice. Five healthy volunteers were enrolled to assess the safety, biodistribution, and dosimetry of [18F]PFPMD. Subsequently, 14 NSCLC or CRC patients with or without the KRASG12C mutation underwent [18F]PFPMD and [18F]FDG PET/CT imaging. The SUVmax of tumor uptake of [18F]PFPMD was measured and compared between patients with and without the KRASG12C mutation. Results: [18F]PFPMD was obtained with a high radiochemical yield, radiochemical purity, and stability. The protein-binding assay showed that [18F]PFPMD selectively binds to the KRASG12C protein. [18F]PFPMD uptake was significantly higher in H358 than in A549 and was decreased by pretreatment with AMG510 (H358 vs. A549: 3.22% ± 0.28% vs. 2.50% ± 0.25%, P < 0.05; block: 2.06% ± 0.13%, P < 0.01). Similar results were observed in tumor-bearing mice on PET imaging (H358 vs. A549: 3.93% ± 0.24% vs. 2.47% ± 0.26% injected dose/g, P < 0.01; block: 2.89% ± 0.29% injected dose/g; P < 0.05). [18F]PFPMD was safe in humans and was excreted primarily by the gallbladder and intestines. The whole-body effective dose was comparable to that of [18F]FDG. The accumulation of [18F]PFPMD in KRASG12C mutation tumors was significantly higher than that in non-KRASG12C mutation tumors (SUVmax: 3.73 ± 0.58 vs. 2.39 ± 0.22, P < 0.01) in NSCLC and CRC patients. Conclusion: [18F]PFPMD is a safe and promising PET tracer for noninvasive screening of the KRASG12C mutation status in NSCLC and CRC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsColorectal NeoplasmsHumansAnimalsMicePositron Emission Tomography Computed TomographyProto-Oncogene Proteins p21(ras)Fluorodeoxyglucose F18Tissue DistributionPositron-Emission TomographyMutationLung

Stichwörter der Autor:innen

AMG510CRCKRAS mutationNSCLCPET

Substanzen

Proto-Oncogene Proteins p21(ras)Fluorodeoxyglucose F18KRAS protein, human

Autor:innen und Institutionen

  • Department of Nuclear Medicine and State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Department of Nuclear Medicine and State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Xijing Hospital, Fourth Military Medical University, Xi'an, China 13909245902@163.com fmmukf@qq.com.

Zitieren

APA

Li, X., Ye, J., Wang, J., Quan, Z., Li, G., Ma, W., Zhang, M., Yang, W., Wang, J., Ma, T., Kang, F., & Wang, J. (2023). First-in-Humans PET Imaging of KRAS G12C Mutation Status in Non–Small Cell Lung and Colorectal Cancer Patients Using [ 18 F]PFPMD. Journal of Nuclear Medicine, 64(12), 1880-1888. https://doi.org/10.2967/jnumed.123.265715

Vancouver

Li X, Ye J, Wang J, Quan Z, Li G, Ma W, et al. First-in-Humans PET Imaging of KRAS G12C Mutation Status in Non–Small Cell Lung and Colorectal Cancer Patients Using [ 18 F]PFPMD. Journal of Nuclear Medicine. 2023;64(12):1880-1888. doi:10.2967/jnumed.123.265715

BibTeX
@article{Li2023,
  author = {Li, Xiang and Ye, Jiajun and Wang, Jingyi and Quan, Zhiyong and Li, Guiyu and Ma, Wenhui and Zhang, Mingru and Yang, Weidong and Wang, Junling and Ma, Taoqi and Kang, Fei and Wang, Jing},
  title = {First-in-Humans PET Imaging of KRAS G12C Mutation Status in Non–Small Cell Lung and Colorectal Cancer Patients Using [ 18 F]PFPMD},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {12},
  pages = {1880--1888},
  doi = {10.2967/jnumed.123.265715}
}
Kostenlos starten →